Table 4.
Laboratory and clinical characteristics
| Characteristics (all parameters), mean ± SD | CSA group | TAC group | P-value |
|---|---|---|---|
| Creatinine (mg/dL) | |||
| Baseline | 1.1±0.5 | 1.5±0.8 | <0.0001 |
| 2 years after HTX | 1.4±0.4a | 1.7±1.3b | ns |
| MDRD (mL/min*1.73 m2) | |||
| Baseline | 82.4±34.2 | 67.6±40.7 | 0.0030 |
| 2 years after HTX | 61.3±25.0a | 57.6±24.9a | ns |
| Sodium (mmol/L) | |||
| Baseline | 136.5±3.8 | 137.5±3.4 | 0.0428 |
| 2 years after HTX | 138.6±3.5a | 139.2±2.8a | ns |
| Potassium (mmol/L) | |||
| Baseline | 4.2±0.5 | 4.3±0.6 | ns |
| 2 years after HTX | 4.3±0.4b | 4.4±0.5b | ns |
| Serum urea (mg/dL) | |||
| Baseline | 69.7±45.3 | 78.6±41.4 | ns |
| 2 years after HTX | 56.8±20.1a | 57.3±25.8b | ns |
| Uric acid (mg/dL) | |||
| Baseline | 5.9±2.3 | 6.8±2.6 | 0.0075 |
| 2 years after HTX | 6.6±1.9a | 6.8±2.2b | ns |
| Blood glucose trough level (mg/dL) | |||
| Baseline | 117.2±49.7 | 127.0±56.4 | ns |
| 2 years after HTX | 109.2±30.2b | 114.0±37.0b | ns |
| Creatine phosphokinase (U/L) | |||
| Baseline | 23.3±23.3 | 35.9±21.8 | <0.0001 |
| 2 years after HTX | 141.0±157.3a | 150.8±142.9a | ns |
| ASAT (U/L) | |||
| Baseline | 17.3±10.7 | 24.2±16.7 | 0.0007 |
| 2 years after HTX | 16.4±8.3b | 29.8±32.8b | 0.0014 |
| ALAT (U/L) | |||
| Baseline | 35.7±31.3 | 49.0±36.7 | 0.0048 |
| 2 years after HTX | 17.6±13.6a | 24.3±15.2a | 0.0061 |
| GGT (U/L) | |||
| Baseline | 111.7±112.0 | 306.4±271.1 | <0.0001 |
| 2 years after HTX | 30.6±29.7a | 83.3±99.4a | <0.0001 |
| Total blood cholesterol level (mg/dL) | |||
| Baseline | 220.5±56.6 | 198.0±50.1 | 0.0021 |
| 2 years after HTX | 193.7±46.6a | 178.1±35.5a | 0.0252 |
| HDL (mg/dL) | |||
| Baseline | 60.3±22.5 | 61.4±20.6 | ns |
| 2 years after HTX | 48.7±15.6a | 50.1±16.3a | ns |
| LDL (mg/dL) | |||
| Baseline | 128.9±48.1 | 104.2±32.4 | 0.0002 |
| 2 years after HTX | 114.0±30.5a | 95.8±31.4b | 0.0006 |
| Triglycerides (mg/dL) | |||
| Baseline | 184.5±95.5 | 183.1±78.2 | ns |
| 2 years after HTX | 163.2±135.5b | 158.8±84.2a | ns |
| Lactate dehydrogenase (U/L) | |||
| Baseline | 282.9±109.3 | 297.0±104.9 | ns |
| 2 years after HTX | 196.9±86.8a | 252.3±76.1a | 0.0002 |
| Alkaline phosphatase (U/L) | |||
| Baseline | 149.3±96.9 | 145.1±114.4 | ns |
| 2 years after HTX | 106.6±58.9b | 95.9±54.8a | ns |
| Hemoglobin (g/dL) | |||
| Baseline | 11.4±1.3 | 11.0±1.2 | 0.0080 |
| 2 years after HTX | 12.7±1.6a | 12.8±1.8a | ns |
| Thrombocytes (/nL) | |||
| Baseline | 273.3±129.0 | 314.7±136.1 | 0.0189 |
| 2 years after HTX | 244.3±66.5b | 215.8±67.3a | 0.0109 |
| Leukocytes (/nL) | |||
| Baseline | 10.0±5.2 | 10.1±4.5 | ns |
| 2 years after HTX | 6.7±2.0a | 6.3±2.0a | ns |
| Systolic blood pressure (mmHg) | |||
| Baseline | 125.5±14.3 | 120.8±17.5 | 0.0317 |
| 2 years after HTX | 126.2±15.8b | 121.1±14.4b | 0.0405 |
| Diastolic blood pressure (mmHg) | |||
| Baseline | 77.0±9.6 | 73.1±11.20 | 0.0060 |
| 2 years after HTX | 77.2±9.6b | 75.4±10.6b | ns |
Notes:
P<0.05 vs baseline, statistically significant
P<0.05 vs baseline, ns.
Abbreviations: ALAT, alanine aminotransferase; ASAT, aspartate aminotransferase; CSA, cyclosporine A; GGT, gamma-glutamyl transferase; HDL, high-density lipoprotein; HTX, heart transplantation; LDL, low-density lipoprotein; MDRD, Modification of Diet in Renal Disease; ns, not statistically significant; SD, standard deviation; TAC, tacrolimus.